205 related articles for article (PubMed ID: 20471942)
1. DNA binding cooperativity of p53 modulates the decision between cell-cycle arrest and apoptosis.
Schlereth K; Beinoraviciute-Kellner R; Zeitlinger MK; Bretz AC; Sauer M; Charles JP; Vogiatzi F; Leich E; Samans B; Eilers M; Kisker C; Rosenwald A; Stiewe T
Mol Cell; 2010 May; 38(3):356-68. PubMed ID: 20471942
[TBL] [Abstract][Full Text] [Related]
2. Groups of p53 target genes involved in specific p53 downstream effects cluster into different classes of DNA binding sites.
Qian H; Wang T; Naumovski L; Lopez CD; Brachmann RK
Oncogene; 2002 Nov; 21(51):7901-11. PubMed ID: 12420228
[TBL] [Abstract][Full Text] [Related]
3. Ribosomal protein S27-like, a p53-inducible modulator of cell fate in response to genotoxic stress.
Li J; Tan J; Zhuang L; Banerjee B; Yang X; Chau JF; Lee PL; Hande MP; Li B; Yu Q
Cancer Res; 2007 Dec; 67(23):11317-26. PubMed ID: 18056458
[TBL] [Abstract][Full Text] [Related]
4. Dissociation between cell cycle arrest and apoptosis can occur in Li-Fraumeni cells heterozygous for p53 gene mutations.
Delia D; Goi K; Mizutani S; Yamada T; Aiello A; Fontanella E; Lamorte G; Iwata S; Ishioka C; Krajewski S; Reed JC; Pierotti MA
Oncogene; 1997 May; 14(18):2137-47. PubMed ID: 9174049
[TBL] [Abstract][Full Text] [Related]
5. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage.
Seoane J; Le HV; Massagué J
Nature; 2002 Oct; 419(6908):729-34. PubMed ID: 12384701
[TBL] [Abstract][Full Text] [Related]
6. Comparative binding of p53 to its promoter and DNA recognition elements.
Weinberg RL; Veprintsev DB; Bycroft M; Fersht AR
J Mol Biol; 2005 May; 348(3):589-96. PubMed ID: 15826656
[TBL] [Abstract][Full Text] [Related]
7. p53 apoptotic response to DNA damage dependent on bcl2 but not bax in head and neck squamous cell carcinoma lines.
Crowe DL; Sinha UK
Head Neck; 2006 Jan; 28(1):15-23. PubMed ID: 16302195
[TBL] [Abstract][Full Text] [Related]
8. Role for Kruppel-like factor 4 in determining the outcome of p53 response to DNA damage.
Zhou Q; Hong Y; Zhan Q; Shen Y; Liu Z
Cancer Res; 2009 Nov; 69(21):8284-92. PubMed ID: 19826046
[TBL] [Abstract][Full Text] [Related]
9. Multiple response elements and differential p53 binding control Perp expression during apoptosis.
Reczek EE; Flores ER; Tsay AS; Attardi LD; Jacks T
Mol Cancer Res; 2003 Dec; 1(14):1048-57. PubMed ID: 14707288
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase 5 is not a p53 target gene, but its overexpression inhibits tumor cell growth and induces apoptosis.
Huang Y; Tan M; Gosink M; Wang KK; Sun Y
Cancer Res; 2002 May; 62(10):2913-22. PubMed ID: 12019172
[TBL] [Abstract][Full Text] [Related]
11. Physical and functional interactions between members of the tumour suppressor p53 and the Sp families of transcription factors: importance for the regulation of genes involved in cell-cycle arrest and apoptosis.
Koutsodontis G; Vasilaki E; Chou WC; Papakosta P; Kardassis D
Biochem J; 2005 Jul; 389(Pt 2):443-55. PubMed ID: 15790310
[TBL] [Abstract][Full Text] [Related]
12. Decoy receptor 2 (DcR2) is a p53 target gene and regulates chemosensitivity.
Liu X; Yue P; Khuri FR; Sun SY
Cancer Res; 2005 Oct; 65(20):9169-75. PubMed ID: 16230375
[TBL] [Abstract][Full Text] [Related]
13. Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression.
Mirza A; Wu Q; Wang L; McClanahan T; Bishop WR; Gheyas F; Ding W; Hutchins B; Hockenberry T; Kirschmeier P; Greene JR; Liu S
Oncogene; 2003 Jun; 22(23):3645-54. PubMed ID: 12789273
[TBL] [Abstract][Full Text] [Related]
14. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site.
Takimoto R; El-Deiry WS
Oncogene; 2000 Mar; 19(14):1735-43. PubMed ID: 10777207
[TBL] [Abstract][Full Text] [Related]
15. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
[TBL] [Abstract][Full Text] [Related]
16. A transcriptional activation function of p53 is dispensable for and inhibitory of its apoptotic function.
Kokontis JM; Wagner AJ; O'Leary M; Liao S; Hay N
Oncogene; 2001 Feb; 20(6):659-68. PubMed ID: 11313999
[TBL] [Abstract][Full Text] [Related]
17. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements.
Campomenosi P; Monti P; Aprile A; Abbondandolo A; Frebourg T; Gold B; Crook T; Inga A; Resnick MA; Iggo R; Fronza G
Oncogene; 2001 Jun; 20(27):3573-9. PubMed ID: 11429705
[TBL] [Abstract][Full Text] [Related]
18. [Tumor suppressor gene p53: mechanisms of action in cell proliferation and death].
Mendoza-Rodríguez CA; Cerbón MA
Rev Invest Clin; 2001; 53(3):266-73. PubMed ID: 11496714
[TBL] [Abstract][Full Text] [Related]
19. The proliferation-associated early response gene p22/PRG1 is a novel p53 target gene.
Schäfer H; Trauzold A; Sebens T; Deppert W; Fölsch UR; Schmidt WE
Oncogene; 1998 May; 16(19):2479-87. PubMed ID: 9627114
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic mutation of the p53 gene derived from head and neck cancer prevents cells from undergoing apoptosis after DNA damage.
Kawamata H; Omotehara F; Nakashiro K; Uchida D; Shinagawa Y; Tachibana M; Imai Y; Fujimori T
Int J Oncol; 2007 May; 30(5):1089-97. PubMed ID: 17390010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
